BLA 761089 · Teva Pharms USA
Ajovy
Fremanezumab-Vfrm · Injection
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jun 5, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Sep 14, 2018
Approved uses
3
Original approval plus efficacy supplements
Registered trials
32
14 Phase 3, 6 recruiting
FAERS reports
11,839
3,963 serious, 117 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 5, 2026.
AJOVY is indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more. AJOVY is a calcitonin gene-related peptide antagonist indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more. ( 1 )
Mechanism: Fremanezumab-vfrm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 5, 2025 Supplement 31 · Efficacy · priority review LabelLetter
- Jan 27, 2020 Supplement 2 · Efficacy LetterLabel
- Sep 14, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
- AJOVY · FREMANEZUMAB-VFRM 150MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Fremanezumab" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of MigrainePivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT02638103 · 1,890 participants · Start Feb 26, 2016 · Primary completion Jun 6, 2018
Drug: Fremanezumab; Placebo · For: Migraine
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 139 sites in all
- Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic MigrainePivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT02621931 · 1,130 participants · Start Mar 22, 2016 · Primary completion Apr 11, 2017
Drug: Fremanezumab; Placebo · For: Migraine
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 273 sites in all
- Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic MigrainePivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT02629861 · 875 participants · Start Mar 23, 2016 · Primary completion Apr 10, 2017
Drug: Fremanezumab; Placebo · For: Migraine
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 275 sites in all
- An Efficacy and Safety Study of Fremanezumab in Adults With MigrainePivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT03308968 · 838 participants · Start Oct 13, 2017 · Primary completion Oct 2, 2018
Drug: Fremanezumab; Placebo · For: Migraine Prophylaxis
Sites: Huntsville, Alabama; Long Beach, California; San Diego, California · 113 sites in all
- Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic MigrainePivotal-lookingCompleted
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT03303079 · 571 participants · Start Dec 19, 2017 · Primary completion Nov 30, 2019
Drug: TEV-48125; TEV-48125 or placebo and 1 more · For: Migraine
Sites: Iruma, Japan
- A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and AdolescentsPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D LLCTeva (TEVA)
NCT04530110 · 499 participants · Start Sep 16, 2020 · Primary completion Aug 15, 2025
Drug: Fremanezumab · For: Migraine
Sites: Aurora, Colorado; Colorado Springs, Colorado; Jacksonville, Florida · 70 sites in all
- A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With MigrainePivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT05458011 · 365 participants · Start Sep 30, 2022 · Primary completion Jan 31, 2024
Drug: Fremanezumab; Placebo · For: Migraine
Sites: Baotou Shi, China; Beijing, China; Changchun, China · 29 sites in all
- Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic MigrainePivotal-lookingCompleted
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT03303092 · 357 participants · Start Dec 19, 2017 · Primary completion Nov 22, 2019
Drug: TEV-48125; TEV-48125 or placebo and 1 more · For: Migraine
Sites: Iruma, Japan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- accidental exposure to product1,501
- injection site pain1,358
- migraine1,114
- drug ineffective951
- headache778
- injection site erythema685
- device leakage576
- device malfunction521
- fatigue518
- nausea518
- injection site pruritus511
- injection site swelling462
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 177 |
| 2019 | 1,390 |
| 2020 | 1,047 |
| 2021 | 1,421 |
| 2022 | 1,590 |
| 2023 | 1,420 |
| 2024 | 2,163 |
| 2025 | 1,484 |
| 2026 | 1,140 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Fremanezumab in Children and Adolescents with Episodic Migraine.
Hershey AD, Szperka CL, Barbanti P, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Multicenter Study
- Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society.
Pringsheim T, Smith DB, Tanveer S, et al. · Neurology 2026 · Systematic Review
- Fremanezumab for the Preventive Treatment of Chronic Migraine.
Silberstein SD, Dodick DW, Bigal ME, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Multicenter Study
- Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.
Haghdoost F, Puledda F, Garcia-Azorin D, et al. · Cephalalgia 2023 · Systematic Review, Network Meta-Analysis
- Fremanezumab autoinjector pen for the prevention of migraine.
Weatherall MW · Ther Deliv 2021 · Clinical Trial, Phase III
- Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
Messina R, Huessler EM, Puledda F, et al. · Cephalalgia 2023 · Systematic Review, Network Meta-Analysis
Sponsor: Teva
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.